Prevalence and Antifungal Susceptibility of Candida Species Isolated from Women Attending a Gynaecological Clinic in Kumasi, Ghana by Abruquah, HH
Journal of Science and Technology  © KNUST August 201 
PREVALENCE AND ANTIFUNGAL SUSCEPTIBILITY OF 
CANDIDA SPECIES ISOLATED FROM WOMEN ATTENDING 
A GYNAECOLOGICAL CLINIC IN KUMASI, GHANA 
H. H. Abruquah 
Microbiology Department and Infectious Disease, KNUST Hospital, 
KNUST, Kumasi  
ABSTRACT 
Candidal vulvovaginitis causes extreme discomfort and affects the well being of women. The aim 
of this study was to determine the prevalence of Candida infections among women attending 
gynaecological clinic at the Komfo Anokye Teaching Hospital (KATH) in Kumasi and the anti-
fungal susceptibility patterns of the Candida specis isolated. A total of 186 high vaginal swabs 
(HVS) were collected from women suspected of having candidal vulvovaginitis between March 
and June 2009.  Wet mount preparations in potassium hydroxide (KOH) and Gram-stained 
smears were performed directly on specimens. Cultures for Candida species were done using 
sabouraud dextrose agar (SDA) (Oxoid, UK) at room temperature (25 - 28ºC). Antifungal sus-
ceptibility of the Candida species to amphotericin B, fluconazole and itraconazole was assessed 
using the ATB FUNGUS 3 test kits (bioMerieux, Marcy-l’Etoile, France).  Of the 186 HVS cul-
tured, 39 yielded Candida species giving Candida prevalence in HVS during the study period as 
21%. Candida species isolated from HVS specimens were Candida albicans (n=19, 48.7%), Can-
dida glabrata (n=7, 17.9%), Candida tropicalis (n=4, 10.3%) and Candida dubliniensis (n=4, 
10.3%). Other species isolated were Candida sake (n=2, 5.1%), Candida krusei (n=2, 5.1%) and 
Candida parapsilosis (n=1, 2.6%). Susceptibility of the isolates to antifungal agents ranged from 
66.7% to 87.2% with MICs ranging from ≤ 0.125mg/l to 8mg/l. Amphotericin B was the best per-
forming antifungal agents with sensitivity of 87.2%. 
INTRODUCTION  
Yeasts infections of the vagina, commonly 
known as candidal vulvovaginitis, is a female 
infection primarily common during the fecund 
period (Odds, 1988; Sobel, 1992). The preva-
lence of candidal vulvovaginitis in the world is 
estimated in the range of 5 to 20% (Collier et 
al., 1998). Depending on the age, locality and 
socio-economic status, the frequency of vaginal 
Candida isolates has been reported to be be-
tween 5 and 48.4% in women (Abu-Elteen t 
al., 1997). The prevalence of vulvovaginitis 
increases in groups such as pregnant or diabetic 
women, those using oral contraceptives or on 
long-term antibiotic treatment (Sobel, 1992). 
Candida albicans is the most common etiologi-
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 dard equivalent to 2 McFarland. Results were 
read after 24 to 48 hours of incubation at 37◦C. 
The yeast, Candida parapsilosis NCTC 3104, 
was used as quality control strain. Antifungal 
susceptibility results were analyzed using the 
interpretive criteria as recommended by Clini-
cal and Laboratory Standard Institute (CLSI) 
for fluconazole [FCA (S≤ 8mg/l; I: 16-32mg/l 
and R≥ 64mg/l for Candida species)]; itracona-
zole [ITR (S≤ 0.125mg/l; I: 0.25-0.5mg/l and 
R≥ 1mg/l for Candida species)]. For ampho-
tericin B, CLSI interpretive criteria for Candida 
are not available. However, it has been sug-
gested that Candida isolates for which ampho-
tericin B MICs  were ≤ 1mg/l were considered 
susceptible and so it was used as cut off value 
to separate susceptible isolates from the resis-
tant  ones (CLSI, 2002). 
 
RESULTS  
Of the 186 high vaginal swabs cultured, 39 
yielded Candida species (21%). Candida spe-
cies isolated from high vaginal swabs were 
Candida albicans (n=19, 48.7%), Candida 
glabrata (n=7, 17.9%), Candida tropicalis 
(n=4, 10.3%) and Candida dubliniensis (n=4, 
10.3%). Other species isolated were Candida 
sake (n=2, 5.1%), Candida krusei (n=2, 5.1%) 
and Candida parapsilosis (n=1, 2.6%). The 
distribution of different species of Candida 
among the different age groups is shown in 
Table 1. The results obtained also showed that 
the 15-20 year group had the highest frequency 
of Candida positive samples followed by the 26
-30 year age group. The age groups 46-50 years 
and the above 51 year bracket had the lowest 
frequency of Candida (2.6%). Statistical analy-
sis of the data using one sample t- test (SPSS 
version 17) indicates that there was significant 
difference in the prevalence among the differ-
ent age- groups (p- value = 0.004). 
 
The results of the antifungal susceptibility of 
the 39 Candida yeast isolates against ampho-
tericin B fluconazole and itraconazole as deter-
mined by the ATB FUNGUS 3 test method are 
shown in Table 2 below. 
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cal agent of vulvovaginitis but other yeast spe-
cies such as Candida glabrata, Candida krusei 
and Candida tropicalis are also encountered 
(Sobel, 1997). There are no recent published 
data in the literature to ascertain the true preva-
lence of candidal vulvovaginitis in Ghana. The 
aim of this study therefore was to determine the 
prevalence of vulvovaginal candidiasis among 
women attending the Komfo Anokye Teaching 
Hospital in Kumasi and the antifungal suscepti-
bility patterns of the Candida species isolated 
from these women. 
 
MATERIALS AND METHODS 
The study was conducted at the microbiology 
laboratory of the Komfo Anokye Teaching 
Hospital with the approval of the Committee on 
Human Research, Publications and Ethics 
(CHRPE) of the School of Medical Sciences of 
the Kwame Nkrumah University of Science and 
Technology (KNUST) and the Komfo Anokye 
Teaching Hospital (KATH). High vaginal 
swabs routinely delivered at the microbiology 
laboratory for mycological examination were 
further used for this research work. Wet mount 
preparations in KOH and Gram-stained smears 
were performed directly on HVS and then ob-
served using the light microscope for yeast 
cells and hyphae. The samples were cultured on 
sabouraud dextrose agar (SDA) (Oxoid, UK) 
and then incubated at room temperature (25-
28◦C) for 2 to 3 days. Candida yeast cells iso-
lated from the samples were identified to the 
species level using the germ tube test and the
API ID 32 C test kits. The isolates were stored 
as suspension in 20% glycerol broth at -70◦C.  
 
Antifungal susceptibility of the Candida iso-
lates to amphotericin B, fluconazole and itra-
conazole was assessed using the ATB FUN-
GUS 3 test kits (bioMerieux, Marcy-l’Etoile, 
France) according to manufacturer’s instruc-
tion. The range of concentrations of different 
antifungal agents tested was at twofold dilu-
tions and included: amphotericin B [AMB (0.5 
- 16mg/l)]; fluconazole [FCA (1 - 128mg/l)] 
and itraconazole [ITR (0.125 - 4mg/l)]. The 
inoculum size was adjusted to turbidity stan-
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C. C. C. C. C. C. C. 
Total 
(%) 
  albicans glabrata tropicalis dubliniensis krusei sake parapsilosis   
15-20 5.0 3.0 1.0  - 1.0 - - 10(25.6) 
21-25 4.0   -  -  -  - - - 4(10.3) 
26-30 2.0 3.0 1.0 2.0  - 1.0 - 9(23.0) 
31-35   - 1.0 1.0 1.0  - 1.0 1.0 5(12.8) 
36-40 2.0  - 1.0 1.0 1.0 - - 5(12.8) 
41-45 4.0  -  -  -  - - - 4(10.3) 
46-50 1.0  -  -  -  - - - 1(2.6) 
≥51 1.0  -  -  -  - - - 1(2.6) 
Total 
(%) 19 (48.7) 7(17.9) 4(10.3) 4(10.3) 2(5.1) 2(5.1) 1(2.6) 
39
(100.0) 
C: Candida  
DISCUSSION 
Candida infection of the vagina is a common 
problem that causes significant morbidity and 
affects the well being of women (Asticcioli et
al., 2009). The results showed in the studied 
population Candida prevalence of 21% from 
high vaginal swabs. This is lower than the 
40.6% and 51.5% reported by Enweani et al. 
(2001) among non-contraceptive and contra-
ceptive users in Nigeria. The high prevalence 
recorded among the contraceptive users in En-
weani’s study could be attributed to the pres-
ence of oestrogen and progesterone hormones 
in the contraceptive that increased glycogen 
level in the vaginal fluid and hence promoted 
the overgrowth of Candida species (Rippon, 
1988; Njoku-Obi et al., 1976). However, the 
21% prevalence reported in this study is consis-
tent with findings from studies of the general 
female population (Gross et al., 2007; Mohanty 
et al., 2007; Falleiros de Padua et al., 2003). 
 
This study also showed that the 15-20 year age 
group had the highest frequency (n= 10, 25.6%) 
of Candida isolation from high vaginal swabs 
followed by the 26-30 year age group (n=9, 
23.0%). Statistical analysis of the data using 
one- sample t- test (SPSS version 17) indicates  
that there was significant difference (p-value = 
0.033)  in prevalence between the 15- 20 and 
26- 30 year age groups.  This finding contra-
dicts that of Okungbowa et al. (2003) who re-
ported in Nigeria that the 26-30 year age group  
followed by the 21-25 year group had the high-
est frequency of Candida positive samples in 
their study. Also Ako-Nai et al. (1993) reported 
in Nigeria that the age group 20-25years was 
the group in which genital candidiasis occurs 
most frequently. They suggested in their study 
that there could be a link between the disease 
and sexual activity.  
 
The high prevalence of Candida isolation 
within the 21-30 age groups supports the re-
ports of Enweani et al. (1987) which showed 
that 40.7% of total samples of asymptomatic 
female students of University of Jos, Nigeria 
had vaginal candidiasis. They reported that the 
20-30 year age could be a vulnerable group of 
candidal vulvovaginitis probably due to use of 
contraceptives and increased sexual activity.  
 
The most frequent Candida species isolated 
from high vaginal swab in this study was Can-
dida albicans, followed by Candida glabrata. 
This finding compares favourably with that of  
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other studies in other parts of the world (Ellabib 
and ElJariny, 2001; Asticcioli et al., 2009). 
However, in the study of Okungbowa et al. 
(2003) in Nigeria, it was reported that Candida 
glabrata was the commonest yeast isolated 
from both urinary and high vaginal specimens  
followed by Candida albicans and Candida 
tropicalis, a study in which urinary and high 
vaginal swabs isolates were combined.   
 
Fluconazole is one of the first-line antifungal 
drugs that are used in the treatment of infec-
tions due to Candida species other than Can-
dida krusei and some Candida glabrata isolates 
(Patel, 2000; Wolff et al., 2000). In this study, 
it was found that none of the 19 Candida albi-
cans isolated from high vaginal swabs was re-
sistant to fluconazole even though 26.3% (5/19) 
were in the intermediate category. This finding 
is consistent with findings of Sobel et al. 
(2004) who reported no fluconazole resistance 
among the 401 Candida albicans recovered 
from women with candidal vaginitis in USA.  
Also Ribeiro et al. (2000) reported in Brazil 
that all the 56 Candida albicans tested against 
fluconazole were susceptible. However, another 
study in USA reported fluconazole resistance to 
be 3.6% among Candida albicans isolates col-
lected from candidal vaginitis patients (Sobel et 
al., 2003). The finding of 26.3% (5/19) of Can-
dida albicans isolates in the intermediate cate-
gory of the sensitivity testing could be consid-
ered alarming because it is an indication of the 
potential for development  of fluconazole resis-
tance. 
 
Findings from the study showed 71.4% of Can-
dida glabrata isolates were found to be in the 
intermediate category for fluconazole which 
confirms those reported in earlier studies that 
Candida glabrata isolates often generate a high 
fluconazole MICs (Pfaller, 1999; Arzeni et al., 
1997; Richter et al., 2005). Resistance of iso-
lates to itraconazole and amphotericin B ranged 
from 7.7 to 12.8% respectively. This compares 
with the result of Araj et al. (1998).  
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CONCLUSION 
The prevalence of vulvovaginal candidiasis  
among women attending gynaecological clinic 
at the Komfo Anokye Teaching Hospital in 
Kumasi was 21%. Candida albicans was the 
most frequent yeast isolated from high vaginal 
swabs followed by Candida glabrata. Ampho-
tericin B was found to be the best performing 
antifungal agents against the vaginal Candida 
isolates with susceptibility rate of 87.2%.    
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